CP220629 | 162141-96-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: CP220629
• 英文别名: 7H-Pyrazolo(3,4-C)pyridin-7-one, 1-cyclopentyl-3-ethyl-1,4,5,6-tetrahydro-6-(2-methylphenyl)-；1-cyclopentyl-3-ethyl-6-(2-methylphenyl)-4,5-dihydropyrazolo[3,4-c]pyridin-7-one
• CAS: 162141-96-0
• 化学式: C₂₀H₂₅N₃O
• 分子量: 323.438
• InChiKey: IPUJXWMHZRFSAT-UHFFFAOYSA-N

物化性质

• 熔点：
  134-135 °C
• 沸点：
  522.7±50.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(2-甲基苯基)-2-吡咯里嗪酮 在 sodium hydroxide 、 sodium methylate 作用下， 以 甲醇 、 乙醚 、 乙醇 、 1,2-二氯乙烷 、 苯 为溶剂， 反应 7.75h， 生成 CP220629
  参考文献：
  名称：

  7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as Novel Inhibitors of Human Eosinophil Phosphodiesterase

  摘要：

  High-throughput file screening against inhibition of human lung PDE4 led to the discovery of 3-ethyl-1-(4-fluorophenyl)-6-phenyl-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine (11) as a novel PDE4 inhibitor. Subsequent SAR development, using an eosinophil PDE assay, led to analogues up to 50-fold more potent than 11 with IC50 values of 0.03-1.6 mu M. One such compound, CP-220,629 (22) (IC50 = 0.44 mu M), was efficacious in the guinea pig aerosolized antigen induced airway obstruction assay (ED50 2.0 mg/kg, po) and demonstrated a significant reduction in eosinophil (55%), neutrophil (65%), and IL-1 beta (82%) responses to antigen challenge in atopic monkeys (10 mg/kg, po).

  DOI：

  10.1021/jm9800090

文献信息

• [EN] 4-METHOXYACRIDINE-1-CARBOXAMIDE DERIVATIVES AND THE PHENAZINE AND OXANTHRENE ANALOGS AS PDE4-INHIBITORS FOR THE TREATMENT OF ASTHMA AND CHRONIC PULMONARY DISEASE (COPD)<br/>[FR] DERIVES DE 4-METHOXYACRIDINE-1-CARBOXAMIDE ET LES ANALOGUES PHENAZINE ET OXANTHRENE UTILISES COMME INHIBITEURS PDE4 POUR LE TRAITEMENT DE L'ASTHME ET LA MALADIE PULMONAIRE CHRONIQUE (COPD)
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2006040650A1

  公开（公告）日：2006-04-20

  The present invention relates to new Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) for treatment of asthma: Ar is a substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclic ring or substituted or unsubstituted heteroaryl ring; each occurrence of L is O, S or NR3; X and A are independently -CRaRb -, -CRa-, -C(=B)-, O, S(O)m, N or NR3; each occurrence of m is 0, 1, or 2; n is 0-4; p is 0-2; Y is -C(=B)C(=D)NR4 or -C(=B)NR4 B is O, S or NRa; D is O, S or NRa; The other substituents are defined in the claims.

  本发明涉及用于治疗哮喘的新磷酸二酯酶4型（PDE4）抑制剂的化学式（1）：Ar是取代或未取代的芳基，取代或未取代的芳基烷基，取代或未取代的杂环环或取代或未取代的杂芳环；每次出现的L是O、S或NR3；X和A独立地是-CRaRb-，-CRa-，-C(=B)-，O，S(O)m，N或NR3；每次出现的m是0、1或2；n为0-4；p为0-2；Y是-C(=B)C(=D)NR4或-C(=B)NR4；B是O、S或NRa；D是O、S或NRa；其他取代基在权利要求中定义。
• [EN] NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES TRICYCLIQUES UTILES POUR TRAITER LES TROUBLES INFLAMMATOIRES ET ALLERGIQUES, PROCEDE DE PREPARATION DE CES COMPOSES ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：GLENMARK PHARMACEUTICALS LTD

  公开号：WO2004037805A1

  公开（公告）日：2004-05-06

  The present invention relates to novel tricyclic compounds useful for the treatment of inflammatory conditions, diseases of the central nervous and insulin resistant diabetes.

  本发明涉及用于治疗炎症性疾病、中枢神经系统疾病和胰岛素抵抗性糖尿病的新型三环化合物。
• NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Gharat Laxmikant Atmaram

  公开号：US20090306082A1

  公开（公告）日：2009-12-10

  The present invention relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, a diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxides, pharmaceutically acceptable solvates thereof and the pharmaceutical compositions containing them which are useful in the treatment of allergic and inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.

  本发明涉及新型磷酸二酯酶4型（PDE4）抑制剂的化学式（1）及其类似物、互变异构体、对映异构体、二对映异构体、位置异构体、立体异构体、多晶型、药学上可接受的盐、适当的N-氧化物、药学上可接受的溶剂化合物以及含有它们的制药组合物，这些制剂在治疗过敏性和炎症性疾病方面具有用途，包括哮喘、慢性支气管炎、特应性皮炎、荨麻疹、过敏性鼻炎、过敏性结膜炎、春季结膜炎、嗜酸性肉芽肿、牛皮癣、类风湿性关节炎、脓毒性休克、溃疡性结肠炎、克罗恩病、心肌再灌注损伤和脑再灌注损伤、慢性肾小球肾炎、内毒素休克和成人呼吸窘迫综合症。
• [EN] NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES HETEROCYCLIQUES POUR LE TRAITEMENT DES AFFECTIONS INFLAMMATOIRES ET ALLERGIQUES, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：GLENMARK PHARMACEUTICALS LTD

  公开号：WO2004089940A1

  公开（公告）日：2004-10-21

  The present invention relates to novel heterocyclic compounds, their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-oxides, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. The present invention more particularly relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1), their analogs, their tautomers, their enantiomers, their diasteromers, their regioisomers, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-oxide, their pharmaceutically acceptable solvates and the pharmaceutical compositions containing them. The groups X, Ar, Y, P and R1-R4 are defined in claim 1.

  本发明涉及新颖的杂环化合物，它们的类似物，其互变异构体，其位置异构体，其立体异构体，其对映异构体，其二对映异构体，其多晶形式，其药用可接受盐，其适当的N-氧化物，其药用可接受溶剂和含有它们的药物组合物。本发明更具体地涉及公式（1）的新型磷酸二酯酶4型（PDE4）抑制剂，其类似物，其互变异构体，其对映异构体，其二对映异构体，其位置异构体，其立体异构体，其多晶形式，其药用可接受盐，其适当的N-氧化物，其药用可接受溶剂和含有它们的药物组合物。其中，X、Ar、Y、P 和 R1-R4 组在权利要求书中有定义。
• [EN] NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES AMIDES HETEROCYCLIQUES UTILISES POUR LE TRAITEMENT D'AFFECTIONS INFLAMMATOIRES ET ALLERGIQUES; PROCEDE PERMETTANT DE LES FABRIQUER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：GLENMARK PHARMACEUTICALS LTD

  公开号：WO2004022536A1

  公开（公告）日：2004-03-18

  The present invention relates to novel heterocyclic compounds that inhibit phosphodiesterase type 4 (PDE 4). The compounds are useful for treating inflammatory conditions, diseases of the central nervous systems and insulin resistant diabetes.

  本发明涉及一种新型杂环化合物，可抑制磷酸二酯酶4型（PDE 4）。这些化合物可用于治疗炎症性疾病、中枢神经系统疾病和胰岛素抵抗性糖尿病。